You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Relapsed/Refractory Epithelial

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Ovarian Cancer Trial in Maywood (Decitabine, Carboplatin, Paclitaxel)

Not yet recruiting
  • Ovarian Cancer
  • Maywood, Illinois
    Loyola University Medical Center
Aug 1, 2023

Epithelial Ovarian Cancer Trial in Shanghai (LCAR-M23 cells)

Terminated
  • Epithelial Ovarian Cancer
  • LCAR-M23 cells
  • Shanghai, Shanghai, China
    Shanghai East Hospital
Aug 15, 2022

Ovarian Cancer, Peritoneal Carcinomatosis, Fallopian Tube Cancer Trial in Shanghai (Recombinant oncolytic herpes simplex virus

Recruiting
  • Ovarian Cancer
  • +2 more
  • Recombinant oncolytic herpes simplex virus type 1 (R130)
  • Shanghai, Shanghai, China
    Shanghai Tenth People's Hospital
Mar 26, 2023

Ovarian Cancer Trial in Hangzhou (mesothelin-specific chimeric antigen receptor T cell injection)

Recruiting
  • Ovarian Cancer
  • mesothelin-specific chimeric antigen receptor T cell injection
  • Hangzhou, China
    First affiliated hospital, School of Medicine, Zhejiang Universi
May 12, 2022

Solid Tumors, Soft Tissue Sarcoma, Ewing Sarcoma Trial (Magnetic Resonance-Guided High Intensity Focused Ultrasound,

Not yet recruiting
  • Solid Tumors
  • +8 more
  • Magnetic Resonance-Guided High Intensity Focused Ultrasound
  • Lyso-thermosensitive Liposomal Doxorubicin
  • (no location specified)
Mar 10, 2022

Ovarian Cancer, Relapsed or Refractory, Chiauranib Trial in Shanghai (chiauranib, Placebo, Paclitaxel)

Recruiting
  • Ovarian Cancer
  • +3 more
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Mar 7, 2022

Ovarian Cancer Trial in Shanghai (anti- MESO CAR-T cells, Fludarabine, Cyclophosphamide)

Recruiting
  • Ovarian Cancer
  • anti- MESO CAR-T cells
  • +2 more
  • Shanghai, Shanghai, China
    Shanghai 6th People's Hospital
Aug 9, 2021

Ovarian Cancer Trial in Shanghai (chiauranib, etoposide, paclitaxel)

Completed
  • Ovarian Cancer
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Mar 17, 2021

Relapsed and/or Refractory Multiple Myeloma Trial in Köln (BMS-986453, Fludarabine, Cyclophosphamide)

Not yet recruiting
  • Relapsed and/or Refractory Multiple Myeloma
  • Köln, Germany
    Local Institution - 0017
Dec 4, 2023

Relapsed/Refractory Multiple Myeloma Trial in Suzhou (ICI201)

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Suzhou, Jiangsu, China
    First Affiliated Hospital, Soochow University
Jul 31, 2023

Refractory Cancer, Relapsed Cancer Trial in Weston (Drug Sensitivity Test (DST))

Not yet recruiting
  • Refractory Cancer
  • Relapsed Cancer
  • Drug Sensitivity Test (DST)
  • Weston, Florida
    Lerner College of Medicine: Cleveland Clinic Florida
Sep 1, 2023

Relapsed or Refractory Hodgkin Lymphoma Trial in Beijing (SHR2554+ SHR1701, SHR-1701)

Recruiting
  • Relapsed or Refractory Hodgkin Lymphoma
  • Beijing, Beijing, China
    Han wei dong
Jun 14, 2023

Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small

Recruiting
  • Relapsed or Refractory CD19+ B-cell Lymphoma
  • +2 more
  • TBI-2001
  • +2 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Jul 26, 2023

Relapsed or Refractory B-cell Lymphoma Trial in Guangzhou (infusion of JY231 injection)

Recruiting
  • Relapsed or Refractory B-cell Lymphoma
  • infusion of JY231 injection
  • Guangzhou, Guangdong, China
    Guangdong Second Provincial General Hospital
Sep 17, 2023

PET-CT Imaging in Relapsed/Refractory Acute Leukemias

Not yet recruiting
  • B Cell
  • +2 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Aug 4, 2023

    Relapsed or Refractory Multiple Myeloma Trial (Talquetamab)

    Available
    • Relapsed or Refractory Multiple Myeloma
    • (no location specified)
    Mar 6, 2023

    Relapsed or Refractory Diffuse Large B-cell Lymphoma Trial in Beijing (BEBT-908 for injection)

    Active, not recruiting
    • Relapsed or Refractory Diffuse Large B-cell Lymphoma
    • BEBT-908 for injection
    • Beijing, China
      Cancer Hospital Chinese Academy of Medical Sciences
    Oct 8, 2023

    Relapsed or Refractory B-cell Lymphoma Trial (Relmacabtagene Autoleucel Injection)

    Not yet recruiting
    • Relapsed or Refractory B-cell Lymphoma
    • Relmacabtagene Autoleucel Injection
    • (no location specified)
    Apr 13, 2023

    Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial (Venetoclax)

    Not yet recruiting
    • Multiple Myeloma in Relapse
    • Multiple Myeloma, Refractory
    • (no location specified)
    Oct 30, 2023

    Relapsed or Refractory Multiple Myeloma Trial in Tianjin (YTS104 Cells injection)

    Not yet recruiting
    • Relapsed or Refractory Multiple Myeloma
    • YTS104 Cells injection
    • Tianjin, Tianjin, China
      Institute of Hematology & Blood Diseases Hospital
    Jun 13, 2023

    Light Chain Amyloidosis Trial (FKC288)

    Not yet recruiting
    • Light Chain Amyloidosis
    • (no location specified)
    Jul 30, 2023

    Refractory Solid Tumors Trial in Houston (Eribulin, Irinotecan, Temozolomide)

    Recruiting
    • Refractory Solid Tumors
    • Houston, Texas
      M D Anderson Cancer Center
    Aug 22, 2023

    Relapsed/Refractory Multiple Myeloma Trial in Benowa (ISB 2001)

    Not yet recruiting
    • Relapsed/Refractory Multiple Myeloma
    • ISB 2001
    • Benowa, Queensland, Australia
      Pindara Private Hospital
    May 18, 2023

    Relapsed/Refractory Higher-Risk Myelodysplastic Syndrome, Relapsed/Refractory Acute Myeloid Leukemia Trial (Magrolimab)

    Available
    • Relapsed/Refractory Higher-Risk Myelodysplastic Syndrome
    • Relapsed/Refractory Acute Myeloid Leukemia
    • Magrolimab
    • (no location specified)
    Jan 18, 2023

    Relapsed or Refractory Multiple Myeloma Trial (Forimtamig, Carfilzomib, Daratumumab)

    Not yet recruiting
    • Relapsed or Refractory Multiple Myeloma
    • (no location specified)
    Sep 20, 2023